Ecolab Life Sciences And Repligen Launch DurA Cycle Affinity Resin For Large-Scale Biologic Manufacturing

Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of

Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Purolite’s DurA Cycle, a protein A chromatography resin for large-scale purification processes. This new affinity resin is being introduced at the BIO International Convention (BIO 2024), being held June 3-6 in San Diego. This latest innovation marks a significant milestone in Purolite’s long-term strategic partnership with Repligen, further solidifying Ecolab’s dedication to driving advancements in the bioprocessing industry.

DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies, where cost of goods is critical for biologic drug developers. This new resin represents the latest addition to Purolite’s toolbox, following two new resins launched in the last eighteen months to address purification challenges associated with ever-increasingly complex drugs.

Total
0
Shares
Related Posts
Read More

Eni Unit Plenitude Entered New Partnership to Develop 1.5 GW of Wind and Photovoltaic Projects in Italy and Spain

Plenitude - a Società Benefit wholly owned by Eni, has entered a new partnership with Infrastrutture S.p.A. to develop solar and wind power projects in Italy and Spain by acquiring a 65% stake in Hergo Renewables S.P.A., a company that holds a portfolio of projects in the two countries with a total capacity of approximately 1.5GW. Infrastrutture will retain the remaining 35% stake.

E